Company Filing History:
Years Active: 2021-2025
Title: Innovations by Inventor Bettina Van Lengerich in Antibody Development
Introduction: Bettina Van Lengerich, an accomplished inventor based in South San Francisco, CA, is making significant strides in the field of biomedicine. With a strong focus on the development of anti-TREM2 antibodies, she holds two patents that contribute to advancing therapeutic methods targeting neurological disorders.
Latest Patents: Bettina's recent patents, titled "Anti-TREM2 antibodies and methods of use thereof," focus on antibodies that specifically bind to the human triggering receptor expressed on myeloid cells 2 (TREM2) protein. These innovative antibodies aim to decrease levels of soluble TREM2 (sTREM2) and enhance TREM2 activity, potentially leading to breakthroughs in the treatment of various diseases related to the central nervous system.
Career Highlights: Currently, Bettina is affiliated with Denali Therapeutics Inc., a biotechnology company that emphasizes the development of transformative therapies for neurodegenerative diseases. Her work there underscores her commitment to pushing the boundaries of scientific knowledge and improving patient outcomes.
Collaborations: Throughout her career, Bettina has collaborated with esteemed colleagues, including Kathryn M Monroe and Joshua I Park. These partnerships not only enhance the innovative potential of her work but also contribute to a rich collaborative environment that drives scientific progress in the field of immunology.
Conclusion: Bettina Van Lengerich stands out as a pioneering inventor whose contributions in the area of anti-TREM2 antibodies represent critical advancements in neurobiology. Her work at Denali Therapeutics Inc. demonstrates a commitment to innovation that could have far-reaching implications for the treatment of neurological conditions. As she continues to develop her ideas and patents, the scientific community looks forward to the potential impacts of her research.